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Introduction
Leptin is one of the most important hormones secreted 
by the adipocytes [1]. Besides regulating food intake and 
energy expenditure [2], leptin plays an essential role in 
hematopoiesis, reproductive function, and glucose and 
lipid metabolism [3]. More recently, leptin has also been 
linked to cancer [4]. Enhanced expressions of leptin and 
its receptor (Ob- R) are found in solid cancers including 
breast and ovarian cancers, and have been associated to 
metastasis and poor prognosis [5, 6]. However, conflicting 
evidence exists in the context of cancer incidence. For 
instance, in a meta analysis comprising 23 case–control 
studies, a protective effect of serum leptin against post-
menopausal breast cancer was reported [7]. In contrast, 
a positive association was seen in recent nested case–control 
studies, where serum leptin was measured prospectively 
prior to diagnosis in breast cancer cases [8, 9]. Meanwhile, 
circulating Ob- R has been linked to a lower risk of colo-
rectal cancer in a nested case–control study despite a null 
finding for leptin [10]. These inconsistent findings may 
reflect an involvement of other factors in the relationship 
between leptin and carcinogenesis, as well as potential 
time- sensitivity of this association.
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Abstract
Adipokines, such as leptin, may affect cancer through its link with inflammation 
and obesity. We investigated the association between leptin, C- reactive protein, 
and risk of cancer death while accounting general and abdominal obesity. From 
the Third National Health and Examination Survey (NHANES III), we selected 
5957 adult men and women with baseline measurements of serum leptin and 
CRP. Multivariable Cox regression was used to assess leptin and CRP levels 
(low, moderate, high) in relation to risk of cancer death. Stratification analyses 
were performed for obesity as defined by body mass index (BMI) and waist 
circumference. Fine and Gray regression was performed to account for death 
from cardiovascular disease and other causes as competing events. A total of 
385 participants died of cancer during a mean follow- up of 18 years. After 
adjusting for BMI and waist circumference, an inverse association with log- 
transformed leptin was found for women, with a hazard ratio (HR) of 0.81 
(95% confidence interval [CI]: 0.51–1.30) and 0.40 (95% CI: 0.24–0.68) for 
moderate and high compared to low levels of leptin, respectively; Ptrend = 0.0007). 
No association for leptin was observed in men, but higher CRP corresponded 
to increased risk of dying from cancer (HR: 2.98; 95% CI: 1.57–5.64 for the 
highest vs. lowest categories of CRP). Similar associations were observed with 
competing risk analysis also adjusted for BMI and waist circumference. Con-
trasting associations of serum leptin and CRP with cancer mortality may indicate 
sex- specific biological or environmental pathways linking obesity and cancer in 
men and women which warrant mechanistic investigations.
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Obesity may promote the development of cancer [11], 
but their mechanistic association remains unclear. There 
is indication that chronic inflammation may mediate 
obesity and cancer [12]. Interestingly, a role of leptin 
in inflammation has been suggested [13], as shown by 
a linear association between leptin and markers of in-
flammation [14]. Both increased inflammatory activity 
and leptin production are common features of obesity 
[15], thus it remains unclear whether pathways linking 
obesity and the development of cancer involve leptin 
production or inflammation, or whether there are si-
multaneous effects of these two processes on cancer 
susceptibility.
Presently, there is lack of observational studies assessing 
leptin in relation to cancer while accounting for inflam-
mation and different definitions of obesity. Therefore, we 
sought to disentangle this complex association between 
leptin, inflammation and cancer by assessing serum levels 
of leptin and C- reactive protein (CRP), a common in-
flammatory marker [16], in relation to cancer mortality 
in the Third National Health and Nutrition Examination 
Survey (NHANES III) while accounting for general and 
abdominal obesity. Additionally, since both markers are 
linked to death from cardiovascular disease [17], we used 
cardiovascular mortality as a competing outcome in our 
analysis.
Methods
Study population
The National Center for Health Statistics (NCHS) con-
ducted NHANES III between 1988 and 1994 and designed 
it as a multistage stratified, clustered probability sample 
of the U.S. civilian noninstitutionalized population who 
was at least 2 months old. All subjects participated in 
an interview conducted at home and an extensive physi-
cal examination, which included a blood sample taken 
in a mobile examination center [18]. Despite a cross- 
sectional design, mortality follow- up was provided by 
the NCHS through December 31, 2011, allowing the use 
of the dataset as a prospective cohort [19]. From re-
cruited NHANES III participants, we selected 5957 men 
and women aged 20 and over who had baseline meas-
urements of serum leptin and CRP, available information 
on body mass index (BMI) and waist circumference, 
and for whom follow- up information was available. No 
participant reported a history of any cancer at the base-
line interview. The protocols for the conduct of NHANES 
III were approved by the Institutional Review Board of 
the NCHS, Centers for Disease Control and Prevention. 
Written informed consent was obtained from all par-
ticipants [18].
Serum leptin and CRP measurements
Serum specimens were stored at −70°C and went through 
at least one freeze–thaw cycle during a mean of 8 year of 
storage before leptin concentrations were measured. Serum 
leptin was measured by radioimmunoassay at Linco Research, 
Inc. (St Charles, MO) [20]. The minimum detectable con-
centration of the assay is 0.5 ng/mL. Within- and between- 
assays coefficients of variation were <5%. Levels of serum 
leptin were categorized into low, moderate, and high based 
on sex- specific tertiles [21], with cut- off points of 3.3 and 
6.3 μg/L for men and 10.8 and 20 μg/L for women. Serum 
CRP was measured with an automated Behring Nephelometer 
Analyzer System (Behring Diagnostics, Inc, Somerville, NJ) 
[22]. Coefficients of variation ranged from 3.2 to 16.0% 
throughout data collection. Tests were repeated for specimens 
with results of >10 mg/L. Because levels of CRP below 
2.2 mg/L were undetectable in the NHANES III, we used 
clinical cut- off points as previously described [16]: low 
(<2.2 mg/L), moderate (2.2–10 mg/L), and high (≥10 mg/L).
Covariates
Information on age (years), race/ethnicity (non- Hispanic 
white, non- Hispanic black, Mexican American, and other), 
cigarette smoking (never, former, and current smokers), 
alcohol consumption (never, up to once/week, 2–3 times/
week, 4–6 times/week, daily or more), vigorous physical 
activity (yes, no), and self- reported history of cancer (yes, 
no) was collected during the interview. Socioeconomic 
status was estimated with poverty- to- income ratio (PIR), 
a ratio of total family income to the official poverty 
threshold at the family level. A PIR <1 indicated that 
income was less than the level of poverty. We categorized 
PIR in this study into <1, 1–2, and ≥2.
Obesity status
Body measurements were performed using standardized 
methods and equipment [23]. Weight was measured in 
pounds and automatically converted to kilograms with 
an electronic weight scale. Participants only wore under-
wear, disposable paper gowns, and foam rubber slippers. 
Standing height was measured with a fixed stadiometer 
to the nearest 1 mm. Body mass index (BMI) was cal-
culated as weight in kilograms divided by the square of 
the height in meters. Waist circumference was measured 
at the high point of the iliac crest at minimal respiration 
using a steel measuring tape to the nearest 1 mm [23]. 
General obesity (obese, not obese) was defined as having 
a BMI of 30 kg/m2 or more [24]. Abdominal obesity 
(obese, not obese) was defined as waist circumference of 
>102 cm in men and >88 cm in women [25].
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Mortality and follow- up
Information on dates and causes of death was obtained 
from data linkage of the NHANES dataset with the National 
Death Index (NDI). This linkage was performed by the 
NCHS through probabilistic matching with social security 
number, birth date, occupation, and other personal data, 
and confirmation with death certificate when possible [19]. 
Follow- up time was calculated from interview date/exami-
nation date until date of death or end of study (31 December, 
2011), whichever came first. Underlying causes of death 
were based on ICD- 9 codes through 1998 and on 
International Classification of Diseases, 10th version (ICD- 
10) codes for deaths occurring after 1998. In order to 
adjust for changes between the two coding systems, final 
cause of deaths occurring prior to 1999 were re- coded 
into comparable ICD- 10- based underlying cause of death 
groups [19]. The primary outcome of this study was cancer- 
specific death (ICD- 10: C00- C97). Only aggregate informa-
tion on leading causes of death is available in the 2011 
mortality follow- up, thus rendering analysis by specific 
cancer sites not possible. Death from major cardiovascular 
diseases (ICD- 10: I00- I09, I11, I13, I20- I51, I60- I69) and 
other causes were assessed as competing outcomes.
Statistical analysis
Sampling weights for NHANES III were used to account 
for sampling variability and to adjust for differential prob-
ability of selection of persons [18]. Due to differential dis-
tribution of serum leptin in men and women, we performed 
our analysis for men and women separately. Cox proportional 
hazards regression was used to assess risk of cancer death 
by categories of CRP and leptin. A test for trend was con-
ducted by using assignment to categories as an ordinal scale. 
First, we carried out our analyses using two multivariable 
models: the first was adjusted for age, race/ethnicity, PIR, 
tobacco smoking, alcohol consumption, and vigorous physi-
cal activity. The final model included BMI and waist cir-
cumference to account for the effects of obesity. A test for 
multiplicative interaction between leptin and CRP was per-
formed based on the suggested correlation between the two 
variables [21]. To further elucidate potential effect modifica-
tion by obesity [16], we stratified our analysis based on 
general obesity status while adjusting for waist circumference, 
and by abdominal obesity while adjusting for BMI. In ad-
dition to interaction between leptin and CRP, we also as-
sessed the interaction of each marker with obesity status. 
Finally, since the association of both markers and cardio-
vascular death [17] may affect their impact on cancer mor-
tality, we performed Fine and Gray regression with deaths 
from major cardiovascular diseases and other causes as 
competing outcomes. The Fine and Gray analysis has been 
used to predict cumulative incidence of primary outcome 
in presence of competing outcomes, which may have cre-
ated a competing risks situation [26]. We treated categories 
of leptin and CRP as ordinal variables and adjusted the 
models for age, race/ethnicity, PIR, tobacco smoking, alcohol 
consumption, vigorous physical activity, BMI, and waist 
circumference. Statistical significance was defined as two- 
sided P- values <0.05. All analyses were conducted with SAS 
release 9.3 (SAS Institute, Cary, NC) and R version 3.1.0 
(R Foundation for Statistical Computing, Vienna, Austria).
Results
During a mean follow- up of 18 years, a total of 385 
participants died of cancer and 507 from major cardio-
vascular diseases. Table 1 showed weighted characteristics 
of study participants by sex. Overall, increased leptin levels 
were observed in men and women following higher cat-
egories of CRP, BMI, and waist circumference (Fig. 1), 
Table 1. Weighted characteristics of study population by sex.
Men (N = 2759) Women (N = 3198)
Age (years) – Mean (SD) 42.64 (0.55) 43.81 (0.60)
Follow- up (years) 
– Median (IQR1)
19.35 (17.53–20.95) 19.38 (17.65–20.94)
Race – Ethnicity (%)
Non- Hispanic white 76.52 76.42
Non- Hispanic black 9.77 11.32
Mexican American 5.56 4.78
Other 8.16 7.48
Poverty- to- income ratio
<1 16.34 19.89
1–2 19.09 19.97
≥2 64.57 60.14
Alcohol consumption (%)
Never 35.09 51.69
Up to once/week 18.15 21.28
2–3 times/week 16.50 13.11
4–6 times/week 15.44 8.19
Daily or more 14.82 5.73
Smoking behavior (%)
Never 36.36 55.53
Former 32.29 20.13
Current 31.35 24.34
Vigorous Physical 
activity (%)
11.47 8.48
Waist circumference  
(cm) – Mean (SD)
95.50 (0.48) 88.22 (0.47)
Body mass index (kg/m2)
<18.5 0.68 2.981
18.5–25 38.57 46.04
25–30 40.46 27.06
≥30 20.28 24.09
Cancer death (%) 4.72 5.15
Cardiovascular death (%) 6.34 4.80
1Interquartile range.
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with the highest concentrations of leptin seen in men 
and women with high CRP and BMI ≥ 30 kg/m2 or the 
upper category of waist circumference.
When we examined the association between serum leptin 
or CRP and cancer death with the first model, high levels 
of CRP in men corresponded to higher risk of dying from 
cancer, with a hazard ratio (HR) of 2.98 and 95% confi-
dence interval (CI) of 1.57 to 5.64 for the highest category 
of CRP compared to the lowest. No association was observed 
between leptin and cancer death in both sexes (Table 2). 
We further adjusted this model for obesity indicators, BMI 
and waist circumference, and no changes were seen with 
CRP. However, this revealed a marked inverse association 
between serum leptin and risk of cancer death in women 
(HR: 0.81; 95% CI: 0.51–1.30 and 0.40; 95% CI: 0.51–1.30 
for moderate and high compared to low levels of leptin, 
respectively; Ptrend = 0.0007). No interaction between cat-
egories of leptin and CRP was observed (Table 2).
We sought to further unpick the effect of obesity by 
stratification analyses based on general and abdominal 
obesity status. In men, no association between serum leptin 
and cancer death was observed (Table 3). For CRP, higher 
levels in men without general obesity was observed (HR: 
3.62; 95% CI: 1.86–7.04 for high compared to low CRP, 
Ptrend = 0.004). Interestingly, a higher risk of cancer death 
with the highest CRP levels was also seen in men with 
abdominal obesity (HR: 3.43; 95% CI: 1.03–11.48 com-
pared to low CRP) but not those without. Nevertheless, 
no significant interaction between each definition of obesity 
and CRP was found. On the other hand, higher serum 
leptin was inversely associated with cancer death in women 
with or without general obesity, for example, HR among 
women with BMI <30 kg/m2 was 0.76 (95% 0.44–1.32) 
and 0.30 (0.14–0.65) for moderate and high levels com-
pared to low leptin, respectively (Ptrend = 0.003). Results 
were less clear in stratification by waist circumference, or 
when CRP was assessed (Table 3). No strong interaction 
between leptin and CRP was suggested, although among 
men with abdominal obesity, interaction approached sta-
tistical significance (P = 0.07). Nevertheless, in a follow- up 
analysis when we included leptin and CRP in the same 
model, similar findings were observed.
Figure 1. Serum concentrations of leptin by C- reactive protein (CRP) clinical cut- offs and body mass index in men (A) and women (B), and by CRP 
clinical cut- offs and waist circumference in men (C) and women (D).
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Finally, to account for competing risks, we ran Fine and 
Gray regression to estimate cumulative mortality of cancer 
over time with levels of leptin or CRP as the predictor 
variable and deaths from major cardiovascular diseases and 
other causes as competing outcomes. The analysis was ad-
justed for all potential confounders including BMI and 
waist circumference. Men with higher CRP were shown 
to have higher cumulative mortality from cancer over time 
(P = 0.009), whereas no association for serum leptin was 
found (Ptrend = 0.17). In women, serum CRP was not 
suggested to correlate with cancer mortality (P = 0.59). 
On the other hand, higher cumulative mortality from cancer 
was noted in women with higher serum leptin (P = 0.006). 
Therefore, our results from the competing risk analysis 
corroborated our findings from Cox regression models.
Discussion
This study was based on a nationally representative sample 
of the U.S. population. We observed a protective effect 
of leptin against cancer death in women and higher cancer 
death with increased CRP in men. No marked interaction 
between leptin and CRP was found. Similar associations 
were observed when competing risk analyses with deaths 
from major cardiovascular diseases and other causes as 
competing outcomes were employed.
Proposed mechanisms linking leptin and carcinogenesis 
mostly suggest that higher leptin exposure increases pre-
disposition to the disease [3]. The long isoform of leptin 
receptor (Ob- R) is similar to a type I cytokine receptor, 
with an ability to activate downstream JAK/STAT signaling 
pathway, a known transcription activator for genes involved 
in cell proliferation, survival, angiogenesis, and metastasis 
[27]. Furthermore, the activation of ObR may lead to 
phosphorylation of insulin receptor substrate (IRS- 1), 
initiating activation of PI3K/Akt pathway, which is also 
important in carcinogenesis [28]. Besides directly eliciting 
cancer- related signaling, leptin also displays proinflamma-
tory properties [29]. Inflammation may also promote 
cancer by activation of signaling molecules including STAT3 
and NF- κB [30]. Despite suggestive experimental findings, 
there is limited observational evidence documenting the 
importance of leptin- inflammation interplay in cancer 
incidence or mortality.
Table 2. Sex- specific associations of serum leptin and C- reactive protein (CRP) with cancer death in the NHANES III.
N cancer death/N total
HR (95% CI)
Model 11 Model 22
Men
Leptin (μg/L)
Low 49/909 1.0 (Reference) 1.0 (Reference)
Moderate 71/962 0.87 (0.51–1.49) 0.75 (0.43–1.35)
High 79/964 0.86 (0.50–1.47) 0.60 (0.26–1.33)
Ptrend 0.60 0.22
CRP (mg/L)
Low 195/2047 1.0 (Reference) 1.0 (Reference)
Moderate 56/596 1.33 (0.82–2.18) 1.31 (0.85–2.04)
High 34/192 2.98 (1.57–5.64) 2.90 (1.52–5.53)
Ptrend 0.003 0.002
Pinteraction leptin and CRP 0.13 0.13
Women
Leptin (μg/L)
Low 54/1081 1.0 (Reference) 1.0 (Reference)
Moderate 71/1096 1.19 (0.74–1.91) 0.81 (0.51–1.30)
High 61/1128 0.93 (0.57–1.51) 0.40 (0.24–0.68)
Ptrend 0.80 0.0007
CRP (mg/L)
Low 103/2027 1.0 (Reference) 1.0 (Reference)
Moderate 58/914 1.41 (0.84–2.38) 1.19 (0.67–2.11)
High 25/364 1.10 (0.61–1.99) 0.86 (0.45–1.63)
Ptrend 0.28 0.99
Pinteraction leptin and CRP 0.72 0.81
1Adjusted for age (continuous) and waist circumference, race/ethnicity, poverty- to- income ratio (PIR), tobacco smoking, alcohol consumption, and 
vigorous physical activity.
2Adjusted for age (continuous) and waist circumference, race/ethnicity, PIR, tobacco smoking, alcohol consumption, vigorous physical activity, body 
mass index (continuous) and waist circumference (continuous), and waist circumference.
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Findings from population- based studies for the link 
between leptin and cancer are scarce. Some evidence sug-
gests a positive association between prediagnostic serum 
leptin and risk of cancer for colorectal [31], breast [8], 
prostate [32], and endometrial cancer [33], as well as 
renal cell carcinoma [4], but results are contradictory [34, 
35]. In a large nested case–control study based on the 
European Prospective Investigation into Cancer and 
Nutrition (EPIC), no association was reported between 
serum leptin and risk of colorectal cancer regardless further 
adjustment for BMI (RR: 0.85 (95% CI: 0.56–1.29) for 
the highest quintile compared to the lowest; Ptrend = 0.76) 
[10]. We found a lack of association between leptin and 
cancer death, whereas CRP was positively associated to 
cancer death in men. The inverse association for leptin, 
which was not observed in previous studies such as the 
EPIC Study focusing on colorectal cancer [10] might be 
attributed to the use of cancer mortality as an outcome 
instead of cancer incidence. Therefore, it is possible that 
leptin, despite being weakly associated to cancer incidence, 
may reflect susceptibility for fatal malignancies.
With respect to obesity, leptin and inflammation have 
gained increasing interest with regards to their potential 
implications in cancer development [12]. Leptin resistance 
may occur in obesity [36], where higher levels of leptin 
follow. Interestingly, CRP has been identified as one of 
the major serum leptin- interacting proteins (SLIPs) which 
may worsen leptin resistance [37] and support a biological 
interaction between leptin and CRP in the context of 
diseases. In this study, a nearly statistically significant 
interaction between leptin and CRP was observed in men 
with abdominal obesity. Romero- Corral and colleagues 
[21] stated that such interaction occurs when assessing 
cardiovascular disease, resulting in a weaker association 
between CRP and cardiovascular disease after adjustment 
for leptin. Nevertheless, we did not observe any alteration 
Table 3. Sex- specific associations of serum leptin and C- reactive protein (CRP) with cancer death in the NHANES III, stratified by obesity status. All 
models were adjusted for age, race/ethnicity, poverty- to- income ratio (PIR), tobacco smoking, alcohol consumption, and vigorous physical activity.
General obesity1 Abdominal obesity2
Not obese Obese Not obese Obese
Men
N cancer death/N total 145/2177 43/582 114/1965 74/794
Leptin (μg/L)
 Low 1.0 (Reference) 1.0 (Reference) 1.0 (Reference) 1.0 (Reference)
 Moderate 0.85 (0.50–1.44) 1.18 (0.22–6.40) 0.91 (0.47–1.76) 4.09 (0.88–19.10)
 High 0.61 (0.24–1.53) 1.56 (0.35–6.94) 0.64 (0.20–1.99) 2.71 (0.64–11.45)
 Ptrend 0.28 0.56 0.49 0.59
 Pinteraction leptin and obesity 0.52 0.43
CRP (mg/L)
 Low 1.0 (Reference) 1.0 (Reference) 1.0 (Reference) 1.0 (Reference)
 Moderate 0.99 (0.52–1.89) 1.48 (0.41–5.40) 1.06 (0.57–1.97) 1.33 (0.63–2.79)
 High 3.62 (1.86–7.04) 0.59 (0.13–2.72) 2.22 (0.97–5.05) 3.43 (1.03–11.48)
 Ptrend 0.004 0.89 0.17 0.07
 Pinteraction CRP and obesity 0.29 0.64
 Pinteraction leptin and CRP 0.39 0.09 0.11 0.08
Women
N cancer death/N total 112/2235 67/963 52/1438 127/1760
Leptin (μg/L)
 Low 1.0 (Reference) 1.0 (Reference) 1.0 (Reference) 1.0 (Reference)
 Moderate 0.76 (0.44–1.32) 1.77 (0.20–16.16) 1.06 (0.49–2.30) 1.24 (0.64–2.41)
 High 0.30 (0.14–0.65) 0.65 (0.08–5.08) N/A 1.07 (0.55–2.07)
 Ptrend 0.003 0.01 0.15 0.09
 Pinteraction leptin and obesity 0.63 0.41
CRP (mg/L)
 Low 1.0 (Reference) 1.0 (Reference) 1.0 (Reference) 1.0 (Reference)
 Moderate 1.32 (0.66–2.63) 0.89 (0.33–2.36) 1.00 (0.47–2.11) 1.29 (0.70–2.36)
 High 0.65 (0.25–1.68) 0.92 (0.43–1.94) N/A 1.14 (0.62–2.07)
 Ptrend 0.78 0.89 0.40 0.63
 Pinteraction CRP and obesity 0.83 0.35
 Pinteraction leptin and CRP 0.77 0.37 0.92 0.46
1Adjusted for waist circumference (continuous).
2Adjusted for body mass index (continuous).
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in our findings after leptin and CRP were both included 
in the same analysis, thus suggesting minimal interaction 
between serum leptin and CRP with respect to cancer 
mortality as an outcome.
In many studies including ours, serum concentrations 
of leptin are positively correlated with that of CRP regard-
less of obesity [38, 39]. However, we observed different 
effects between leptin and CRP levels on cancer mortality. 
This may signify differential roles between leptin and CRP 
in the scope of cancer, which require further biological 
investigations. From the competing risk analysis where we 
took into account competing outcomes, it was further sug-
gested the inverse association between serum leptin and 
cumulative mortality from cancer in women, and a positive 
association for CRP in men. Our findings therefore indicate 
that the associations between leptin or CRP and cancer 
may be unique and do not resemble the additive effects 
observed with cardiovascular disease [21]. This interesting 
observation may suggest different biological pathways link-
ing leptin and inflammation with cancer, which may involve 
sex- specific biological and environmental factors. Such 
observations thus call for further investigations to assess 
specific cancers and relevant mechanistic approaches.
This strength of this study is its generalizability fol-
lowing the use of nationally representative data of the 
U.S. population. We were able to adjust for potential 
confounders and stratify by overweight status. To our 
knowledge, this is the first study investigating the interac-
tion between leptin and CRP in relation to cancer in the 
population. A limitation of this study is that there was 
no information on cancer incidence, so that we were only 
able to assess these markers in relation to cancer mortal-
ity. In the NHANES, information on causes of death was 
collected by means of probabilistic matching [19]. Although 
we only selected those considered to have eligible mortal-
ity status, potential misclassification may have occurred. 
Low number of cases also hampered our stratification 
analyses, and therefore future studies with sufficient number 
of cases are necessary to further investigate this topic. 
Additionally, our analyses relied on a single measurement 
so that it may be prone to measurement error and within- 
person variation. The laboratory methods used for CRP 
measurement at the time the NHANES III was conducted 
were unable to perform a high sensitivity assay of this 
marker. Nevertheless, serum CRP in the NHANES III 
population was reported to be associated to CRP- related 
genetic variation [40], justifying the usefulness of this 
marker despite its limitation in quantitatively measuring 
low levels of CRP. Finally, abnormal levels of leptin and 
CRP may occur secondary to cancer which may result 
in reverse causation. We have excluded participants with 
cancer at baseline, however, residual confounding may 
have occurred.
Conclusion
Our study showed that leptin may be inversely associated 
with cancer mortality in women, and CRP corresponded 
with higher risk for cancer death in men. Interaction 
between CRP and leptin is likely to be minimal in the 
study on cancer mortality, unlike previous evidence sug-
gested in cardiovascular disease. It is imperial for further 
studies to address the discrepancies in effects on cancer 
between adipokines and inflammatory markers in order 
to fully comprehend the mechanism linking obesity- related 
features and carcinogenesis. Furthermore, the differential 
associations with cancer death between men and women 
may point toward their potential use in future risk modi-
fication strategies targeting mortality from cancer.
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